 Cytochrome P-450 CYP2D6
"Cytochrome P-450 CYP2D6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR ANTAGONISTS; and TRICYCLIC ANTIDEPRESSANTS. This enzyme is deficient in up to 10 percent of the Caucasian population.
| Descriptor ID |
D019389
|
| MeSH Number(s) |
D08.244.453.040.600 D08.811.682.690.708.170.040.600 D12.776.422.220.453.040.600
|
| Concept/Terms |
Cytochrome P-450 CYP2D6- Cytochrome P-450 CYP2D6
- CYP2D6, Cytochrome P-450
- Cytochrome P 450 CYP2D6
- P-450 CYP2D6, Cytochrome
- CYP2D6
- Cytochrome P450 2D6
- P450 2D6, Cytochrome
- Sparteine Monooxygenase
- Monooxygenase, Sparteine
- Debrisoquine 4-Monooxygenase
- 4-Monooxygenase, Debrisoquine
- Debrisoquine 4 Monooxygenase
- Debrisoquine Hydroxylase
- Hydroxylase, Debrisoquine
- Imipramine 2-Hydroxylase
- 2-Hydroxylase, Imipramine
- Imipramine 2 Hydroxylase
- CYP 2D6
- Debrisoquine 4-Hydroxylase
- 4-Hydroxylase, Debrisoquine
- Debrisoquine 4 Hydroxylase
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2D6".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2D6".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2D6" by people in this website by year, and whether "Cytochrome P-450 CYP2D6" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 0 | 1 | 1 | | 1998 | 4 | 0 | 4 | | 1999 | 2 | 2 | 4 | | 2000 | 2 | 0 | 2 | | 2001 | 0 | 1 | 1 | | 2002 | 3 | 1 | 4 | | 2003 | 3 | 1 | 4 | | 2004 | 2 | 1 | 3 | | 2005 | 4 | 0 | 4 | | 2006 | 2 | 2 | 4 | | 2007 | 3 | 2 | 5 | | 2008 | 4 | 2 | 6 | | 2010 | 5 | 0 | 5 | | 2011 | 4 | 1 | 5 | | 2012 | 1 | 1 | 2 | | 2013 | 7 | 0 | 7 | | 2014 | 7 | 0 | 7 | | 2015 | 5 | 0 | 5 | | 2016 | 4 | 0 | 4 | | 2017 | 4 | 0 | 4 | | 2018 | 5 | 0 | 5 | | 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2D6" by people in Profiles.
-
Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, Gaedigk A, Klein TE, Caudle KE, McCracken JT, de Leon J, Leeder JS. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019 07; 106(1):94-102.
-
Qiao W, Martis S, Mendiratta G, Shi L, Botton MR, Yang Y, Gaedigk A, Vijzelaar R, Edelmann L, Kornreich R, Desnick RJ, Scott SA. Integrated CYP2D6 interrogation for multiethnic copy number and tandem allele detection. Pharmacogenomics. 2019 01; 20(1):9-20.
-
Chamnanphon M, Gaedigk A, Vanwong N, Nuntamool N, Hongkaew Y, Puangpetch A, Sukasem C. CYP2D6 genotype analysis of a Thai population: platform comparison. Pharmacogenomics. 2018 08 01; 19(12):947-960.
-
Lee SB, Wheeler MM, Patterson K, McGee S, Dalton R, Woodahl EL, Gaedigk A, Thummel KE, Nickerson DA. Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model. Genet Med. 2019 02; 21(2):361-372.
-
Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 05; 103(5):770-777.
-
Montané Jaime LK, Paul J, Lalla A, Legall G, Gaedigk A. Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder. Pharmacogenomics. 2018 02; 19(3):197-212.
-
Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, Gaedigk A, Agundez J, Sadhasivam S, Klein TE, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017 08; 102(2):213-218.
-
Chaudhry M, Alessandrini M, Rademan J, Dodgen TM, Steffens FE, van Zyl DG, Gaedigk A, Pepper MS. Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study. Pharmacogenomics. 2017 Apr; 18(5):433-443.
-
Gaedigk A, Twist GP, Farrow EG, Lowry JA, Soden SE, Miller NA. In vivo characterization of CYP2D6*12, *29 and *84 using dextromethorphan as a probe drug: a case report. Pharmacogenomics. 2017 Apr; 18(5):427-431.
-
Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017 07; 102(1):37-44.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|